Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey

NCT04727294 is registered in ClinicalTrials.gov with HealthTree Foundation as lead sponsor.

NCT NCT04727294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04727294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey
Lead sponsor
HealthTree Foundation
Phase
Observational
Overall status
Unknown status
Start date
January 22, 2021
Completion date
December 31, 2021
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, monoclonal gammopathy of undetermined significance, multiple myeloma, smoldering multiple myeloma